The Astrocytoma market is anticipated to increase, due to an increase in the incidence of brain tumors and the anticipated launch of novel therapies.

DelveInsight’s Astrocytoma market report thoroughly explains Astrocytoma, historical and forecasted epidemiology, as well as the Astrocytoma market trends in the 7MM. 

 

Some of the Key Highlights from the Astrocytoma Market Report

• According to Crocetti et al., astrocytic tumor incidence rates vary significantly among European areas, ranging from 3/100,000 in Eastern Europe to 5/100,000 in the United Kingdom.
• According to the National Organization for Rare Disorders (NORD), Anaplastic astrocytoma and glioblastoma multiforme are expected to affect 5-8 persons per 100,000 in the general population.
• Leading players in the Astrocytoma market include Denovo Biopharma, Orbus Therapeutics, Diffusion Pharmaceuticals, and others.
• Key Astrocytoma therapies in the pipeline include DB102, Eflornithine, Trans Sodium Crocetinate (TSC), and others.
• The US FDA and EMA designated DB102 (Denovo Biopharma) as an orphan drug for DLBCL and glioblastoma multiforme (GBM), and the US FDA granted it Fast Track Designation.

 

Have queries? Request for the sample @ Astrocytoma Market Outlook

 

Astrocytoma Overview

Astrocytoma is a tumor that can develop in the brain or the spinal cord. It starts in nerve-supporting cells called astrocytes and is the most frequent type of brain tumor in adults. Astrocytoma is classified as grade 1 (most benign) to grade 4 (most malignant) by the World Health Organization (WHO).

 

Astrocytoma Epidemiology Segmentation

The Astrocytoma report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into: 

• Astrocytoma Total Incident Cases 
• Astrocytoma Grade-Specific Cases 
• Astrocytoma Total Diagnosed Cases 
• Astrocytoma Gender-Specific Cases 
• Astrocytoma Line Wise Treated Cases 

 

Astrocytoma Treatment Landscape

The current Astrocytoma treatment options include:

• Surgery
• Steroids
• Chemotherapy
• Radiotherapy
• Bevacizumab (Avastin)
• Off Label Therapies (Procarbazine hydrochloride)

 

Astrocytoma Market Outlook

The Astrocytoma market will expand during the forecast period, 2021–2030, due to an increase in the incidence of brain tumors and the anticipated launch of novel therapies such as  DB102, Eflornithine, Trans Sodium Crocetinate (TSC), and others.

 

Discover more about the future market share of the drugs @ Astrocytoma Market Analysis

 

Astrocytoma Pipeline Therapies and Key Companies 

•  DB102: Denovo Biopharma
• Eflornithine: Orbus Therapeutics
• Trans Sodium Crocetinate (TSC): Diffusion Pharmaceuticals

 

Table of Contents 

1.	Key Insights
2.	Executive Summary of Astrocytoma
3.	SWOT Analysis of Astrocytoma
4.	Astrocytoma: Market Share (%) Distribution Overview at a Glance: By Country
5.	Epidemiology and Market Methodology
6.	Astrocytoma: Disease Background and Overview
7.	Epidemiology and Patient Population
8.	Epidemiology Scenario: 7MM
9.	The United States Epidemiology
10.	EU-5 Epidemiology
11.	Japan Epidemiology
12.	Current Treatment Practices
13.	Unmet Needs
14.	Patient Journey of Astrocytoma
15.	Key Endpoints in Astrocytoma Clinical Trials
16.	Marketed Therapies
17.	Emerging Therapies
18.	Conjoint Analysis of Astrocytoma
19.	Astrocytoma: Eight Major Market Analysis
20.	7MM Market Size
21.	United States Market Size
22.	EU-5 Market Size
23.	Japan Market Size
24.	Market Access and Reimbursement of Astrocytoma Therapies
25.	Market Drivers
26.	Market Barriers
27.	Appendix
28.	DelveInsight Capabilities
29.	Disclaimer
30.	About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/astrocytoma-market